Kinase News and Research

RSS

ArQule, Daiichi Sankyo initiate enrollment in tivantinib Phase 3 trial for hepatocellular carcinoma

Daiichi Sankyo Company, Limited and ArQule, Inc. today announced that the first patient has been enrolled in the pivotal Phase 3 METIV-HCC (MET-high patients with tivantinib in HCC) trial of tivantinib (ARQ 197).

31 Jan 2013

ADRB receptors play a direct role in Src activation by PKA-mediated mechanism

Scientists at The University of Texas MD Anderson Cancer Center have discovered the signaling pathway whereby a master regulator of cancer cell proteins - known as Src - leads to ovarian cancer progression when exposed to stress hormones. The researchers report in the current issue of Nature Communications that beta blocker drugs mitigate this effect and reduce cancer deaths by an average of 17 percent.

30 Jan 2013

SOD1 enzyme protects cells by regulating cell energy and metabolism

Just like a comic book super hero, you could say that the enzyme superoxide dismutase (SOD1) has a secret identity. Since its discovery in 1969, scientists believed SOD1's only role was to protect living cells against damage from free radicals. Now, researchers at the Johns Hopkins Bloomberg School of Public Health have discovered that SOD1 protects cells by regulating cell energy and metabolism. The results of their research were published January 17, 2013, in the journal Cell.

30 Jan 2013

Tofacitinib fights rheumatoid arthritis progression

Tofacitinib treats symptoms and prevents structural damage in patients with rheumatoid arthritis who do not respond well to methotrexate, indicate phase III trial findings.

29 Jan 2013

TSRI scientists to identify, test and develop drug candidates for several neurodegenerative disorders

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded approximately $1.2 million from the U.S. National Institute of General Medical Sciences of the National Institutes of Health to identify, test and develop a series of drug candidates for a number of diseases, including rheumatoid arthritis, heart disease and several neurodegenerative disorders.

28 Jan 2013

Novartis receives FDA approval for Ph+ acute lymphoblastic leukemia

The U.S. Food and Drug Administration today approved a new use of Gleevec (imatinib) to treat children newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).

27 Jan 2013

Tofacitinib improves disease activity and inhibits progression of joint damage in RA patients

A Phase 3 clinical trial demonstrates that tofacitinib improves disease activity and inhibits progression of joint damage in rheumatoid arthritis (RA) patients who did not respond to methotrexate (MTX).

24 Jan 2013

EMA adopts positive opinion for Pfizer’s bosutinib conditional approval in the EU

Pfizer Inc. announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion regarding the conditional marketing authorization of bosutinib in the European Union for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukemia previously treated with one or more tyrosine kinase inhibitor(s) (TKIs) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.

19 Jan 2013

Cancer Targets & Therapeutics Conference to take place from Feb. 25-26 in Las Vegas

With the rapid progression of molecular biology and genetics, and the subsequent emergence of many new targets, emerging targets & therapeutics provides new opportunities for the prevention and treatment of several major disease systems.

19 Jan 2013

Researchers identify molecular mechanism that regulates autophagy

Researchers at the University of California, San Diego School of Medicine have identified a molecular mechanism regulating autophagy, a fundamental stress response used by cells to help ensure their survival in adverse conditions.

19 Jan 2013

Researchers identify signaling pathway used by malarial parasites to destroy host cells

One of the most insidious ways that parasitic diseases such as malaria and toxoplasmosis wreak their havoc is by hijacking their host's natural cellular processes, turning self against self.

18 Jan 2013

Sabutoclax appears to selectively target leukemia stem cells that are responsible for relapses

Researchers at the University of California, San Diego School of Medicine have discovered that hard-to-reach, drug-resistant leukemia stem cells (LSCs) that overexpress multiple pro-survival protein forms are sensitive - and thus vulnerable - to a novel cancer stem cell-targeting drug currently under development.

18 Jan 2013

Lack or excess of CaM kinase II affects heart muscle cell stiffness

A certain enzyme, the CaM kinase II, keeps the cardiac muscle flexible. By transferring phosphate groups to the giant protein titin, it relaxes the muscle cells. This is reported by researchers led by Prof. Dr. Wolfgang Linke of the Institute of Physiology at the Ruhr Universität in the journal Circulation Research. In failing hearts, which don't pump enough blood around the body, the scientists found an overly active CaM kinase II.

18 Jan 2013

Children's Oakland recruits patients for deferiprone clinical trial to treat PKAN

A groundbreaking, international clinical trial of an iron chelation drug, deferiprone, to treat the rare and devastating neurodegenerative disease, pantothenate kinase-associated neurodegeneration (PKAN), began last month at the trial's only North American site, Children's Hospital & Research Center Oakland.

17 Jan 2013

Miscarriage and molecular signals: an interview with Prof Brosens and Prof Quenby

Miscarriage is defined as the spontaneous loss of pregnancy before the baby reaches viability. Besides the physical trauma, miscarriage causes considerable anxiety, stress, and depression.

17 Jan 2013

Study: Patients with EGFR exon 20 insertions need targeted therapies

Exon 20 insertions are the third most common family of epidermal growth factor receptor (EGFR) mutations found in non-small-cell lung cancer (NSCLC). Little is known about cancers harboring these mutations aside from their lack of response to EGFR tyrosine kinase inhibitors, impairing the development of effective targeted therapies. A recent study published in the February 2013 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, concludes that patients with EGFR exon 20 insertions have similar clinical characteristics to those with common EGFR mutations, but a poorer prognosis.

16 Jan 2013

Tamoxifen can counteract some pathologic features in mouse model of DMD

A new study has found that tamoxifen, a well-known breast cancer drug, can counteract some pathologic features in a mouse model of Duchenne muscular dystrophy (DMD). At present, no treatment is known to produce long-term improvement of the symptoms in boys with DMD, a debilitating muscular disorder that is characterized by progressive muscle wasting, respiratory and cardiac impairments, paralysis, and premature death.

16 Jan 2013

NEDD9 gene controls growth of progenitor cells that give rise to breast tumors

Breast cancer is the second leading cause of cancer deaths among women in the United States. Many of these deaths occur when there is an initial diagnosis of invasive or metastatic disease. A protein called NEDD9-which regulates cell migration, division and survival-has been linked to tumor invasion and metastasis in a variety of cancers.

16 Jan 2013

Biguanide mechanism discovered

Researchers have discovered a novel mechanism by which biguanides exert their glucose-lowering effect, potentially leading to new therapeutic approaches to the treatment of diabetes and insulin resistance.

14 Jan 2013

Blocking interaction of JNK enzyme may counteract neuron destruction

Oxidative stress is a primary villain in a host of diseases that range from cancer and heart failure to Alzheimer's disease, Amyotrophic Lateral Sclerosis and Parkinson's disease.

11 Jan 2013

Kinase News and Research

ArQule, Daiichi Sankyo initiate enrollment in tivantinib Phase 3 trial for hepatocellular carcinoma

ADRB receptors play a direct role in Src activation by PKA-mediated mechanism

SOD1 enzyme protects cells by regulating cell energy and metabolism

Tofacitinib fights rheumatoid arthritis progression

TSRI scientists to identify, test and develop drug candidates for several neurodegenerative disorders

Novartis receives FDA approval for Ph+ acute lymphoblastic leukemia

Tofacitinib improves disease activity and inhibits progression of joint damage in RA patients

EMA adopts positive opinion for Pfizer’s bosutinib conditional approval in the EU

Cancer Targets & Therapeutics Conference to take place from Feb. 25-26 in Las Vegas

Researchers identify molecular mechanism that regulates autophagy

Researchers identify signaling pathway used by malarial parasites to destroy host cells

Sabutoclax appears to selectively target leukemia stem cells that are responsible for relapses

Lack or excess of CaM kinase II affects heart muscle cell stiffness

Children's Oakland recruits patients for deferiprone clinical trial to treat PKAN

Miscarriage and molecular signals: an interview with Prof Brosens and Prof Quenby

Study: Patients with EGFR exon 20 insertions need targeted therapies

Tamoxifen can counteract some pathologic features in mouse model of DMD

NEDD9 gene controls growth of progenitor cells that give rise to breast tumors

Biguanide mechanism discovered

Blocking interaction of JNK enzyme may counteract neuron destruction

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News